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Abstract. in the present study, we investigated the association 
of PDGFRA and KIT mutations as well as PdGFra immu-
nohistochemical expression with clinicopathologic features 
and prognosis in a series of gastrointestinal stromal tumors 
(GiSTs). Tumor dna from 40 GiSTs was sequenced for the 
presence of mutations in KIT exons 9, 11, 13 and 17, and in 
PDGFRA exons 12 and 18. Tissue sections were stained with 
polyclonal anti-PdGFra antibody. KIT mutations occurred in 
26 cases. There were 13 deletions, 6 substitutions, 3 deletion-
substitutions, 3 duplications and 1 insertion. Tumors with KIT 
deletions/insertion were large with a high mitotic index (Mi), 
and were associated with a high rate of symptoms at diag-
nosis, invasion into adjacent organs, distant metastasis, relapse 
and a short disease-free survival (dFS). PDGFRA mutations 
occurred in 6 gastric GiSTs. There were 4 deletions and 
2 substitutions. Tumors with PDGFRA mutations were small, 
with a low Mi and Ki67 score, and were associated with a 
very low rate of symptoms at diagnosis, invasion into adjacent 
organs and distant metastasis. PdGFra immunopositivity 
was found in 23 cases: a peculiar ‘dotlike’ staining was found 
in 5 out of 6 PDGFRA mutated cases. Patients with positive 
PdGFra immunostaining had a longer dFS than those with 
negative staining. Our data confirm that the type of KIT muta-
tion is associated with various clinicopathologic features of 
GiSTs, and indicate that PDGFRA mutations are associated 
with rather indolent tumors. PdGFra immunopositivity 
reflects PDGFRA mutational status and is associated with a 
favorable outcome. 
Introduction
Gastrointestinal stromal tumors (GiSTs) are the most common 
mesenchymal tumors of the gastrointestinal tract. Most GiSTs 
show KIT or platelet-derived growth factor receptor-α (PDGFRA) 
gain-of-function mutations (oncogenic mutations) (1-4). Several 
studies have shown that the type of KIT mutation may be 
correlated with the clinical outcome of patients with GiST. a 
poor prognosis and metastatic behavior were found for GiSTs 
with KIT deletions (5-13) or insertions (5,11,13). By contrast, a 
better prognosis was found for GiSTs with KIT substitutions 
(point mutations) (5,10-12), deletion-substitutions or duplications 
(12,14). However, conflicting results have been reported (15-19).
little is known about PDGFRA mutations. in general, 
PDGFRA mutated cases have a low mitotic rate and good prog-
nosis, and most are gastric GiSTs (4,20). While cd117 expression 
is considered a sensitive marker for KIT activation, there is no 
consensus concerning the reliability of PdGFra antibody as a 
marker (21). However, PdGFra expression has been detected 
by immunohistochemistry in a number of tumors, and these 
results have been confirmed by immunoprecipitation/Western 
blotting experiments (22,23). notably, a strong PdGFra 
immunoreactivity with prominent perinuclear ‘dotlike’ accen-
tuation (so-called Golgi pattern) has been reported to be closely 
associated with PDGFRA mutations (24,25), and was recently 
found in 70.3% of PDGFRA mutated cases (26).
The life expectancy of metastatic GiST patients has 
dramatically changed due to the development of target-based 
molecular therapy with imatinib mesylate and other tyrosine 
kinase inhibitors. The determination of clinicopathological 
and molecular factors predictive of aggressive behavior is 
therefore of key importance. 
in the present study, we analyzed PDGFRA and KIT muta-
tions as well as PdGFra immunohistochemical expression in 
40 patients with GiST in order to investigate the association 
of the type of mutation and PdGFra immunostaining with 
clinicopathologic features and disease prognosis.
Materials and methods
Patients and treatment. a total of 40 adult patients with 
newly diagnosed GiSTs, admitted to the division of Surgical 
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oncology, a.o.u. San Giovanni Battista, Turin, italy, 
from 1996 to 2006, were included in the study. There were 
19 females and 21 males; the mean age was 64.3 years (range 
19-84). diagnosis was established according to the criteria 
of the 2004 GiST consensus conference (27). Twenty-nine 
tumors were located in the stomach, 9 in the small bowel and 
2 in the large bowel. The mean size of the tumors was 6.3 cm 
(range 1-25). according to Fletcher et al (28), the tumors were 
classified based on the risk of aggressive behavior: 4 were 
very low risk, 8 low risk, 11 intermediate risk and 17 high risk. 
GiSTs were subtyped into three histopathologic categories: 
spindle cell, epithelioid or mixed type (28).
after providing their informed consent, the patients 
underwent surgical resection (5 complete radical, 32 limited 
complete and 3 incomplete); 8 also received imatinib mesylate. 
Metastases were present at diagnosis in 3 cases. The follow-up 
was completed on June 30, 2008. The mean follow-up for the 
whole series was 39.6 months (range 2-99). Ten (25%) patients 
relapsed; 5 (12.5%) succumbed to the disease. only the 
disease-free survival (dFS) was considered in the analysis.
Immunohistochemistry. immunohistochemistry was 
performed on 3-µm-thick dewaxed sections using the labeled 
Streptavidin-Biotin 2 System detection kit (dako, Glostrup, 
denmark), diaminobenzidine as chromogen and the mono-
clonal antibodies anti cd34 (clone QBend/10; neomarkers, 
Freemont, ca, uSa), dilution 1:50; Smooth Muscle actin 
(clone1a4; dako), dilution 1:50; Vimentin (cloneV9; dako), 
dilution 1:100; desmin (clone d33; dako), dilution 1:50; 
cd44 (clone dF1485; dako), dilution 1:30; Ki-67 antigen 
(clone MiB-1; dako), dilution 1:100; and polyclonal anti-
bodies anti cd117 (dako), dilution 1:50; S100 (dako), dilution 
1:4,000 and PdGFra (cell Signaling, danvers, Ma, uSa), 
dilution 1:200, following the manufacturer's instructions. in 
particular, PdGFra was applied after antigen retrieval using 
heat-induced epitope retrieval (Hier) in a pressure cooker 
for 2 min in 5 mM of edTa buffer, pH 9, after reaching the 
chamber pressure of 15-25 PSI and temperature of 120˚C. 
PdGFra immunostaining was independently evaluated 
by two pathologists (a.B. and a.F.), who had no knowledge 
of the tumor clinicopathological data and patient survival. 
Staining was scored as negative, weakly positive (Fig. 1a), 
moderately positive (Fig. 1B) and strongly positive (dotlike) 
(Fig. 1c).
For MiB-1 immunoreactivity, the absolute percentage of 
stained cells among at least 1,000 cells from the most active 
areas was recorded, and a cut-off value of 5% was used. 
Molecular analysis. Genomic dna was isolated from 
formalin-fixed paraffin-embedded tissue using xilene-ethanol 
for section deparaffinization and standard proteinase K 
digestion (overnight at 55˚C), followed by extraction using 
the phenol/chloroform method. The quality of the dna 
extracted from the tumor tissue was tested by amplification of 
a 300-bp fragment of the human MHc class ii (Hla-drB) 
gene using the forward primer 5'-ccG GTc Gac TGT ccc 
ccc aGc acG TTT c-3' and reverse primer 5'-Gaa TTc 
TCG CCG CTG CAC TGT GAA GC-3. PCR amplification 
of exons 9, 11, 13 and 17 of the KIT gene (15,29), and of 
exons 12 and 18 of the PDGFRA gene (30,31), was carried 
out as previously described. Pcr products were directly 
purified using paramagnetic bead technology Ampure 
(agencourt Bioscience corp., Beckman coulter S.p.a, 
Milan, italy) according to the manufacturer's protocol. 
direct sequencing of the templates was carried out using the 
Bigdye Terminator cycle Sequencing ready reaction kit v1.1 
(applied Biosystems, Foster city, ca, uSa) according to the 
manufacturer's protocol. Sequencing reactions were purified 
using cleanSeq magnetic beads (agencourt Bioscience corp., 
Beckman coulter S.p.a) according to the manufacturer's 
protocol, and run on an aBi PriSM 310 automated capillary 
system (applied Biosystems). 
Statistical analysis. independence between categorical 
variables and the type of KIT and PDGFRA mutation were 
estimated by the Yates' corrected χ2 test. associations between 
tumor size, mitotic index and Ki67 score, and the type of KIT 
and PDGFRA mutation were assessed by one-way analysis of 
variance (anoVa). univariate dFS analysis was based on 
the Kaplan-Meier product-limit estimates of survival distribu-
tion (32), and differences between survival curves were tested 
using the generalized Wilcoxon test. all data were processed 
with BMdP selected programs (2d, 3d, 7d, 4F and 1l) (33). 
Results
among the 40 GiSTs, 26 (65%) carried KIT mutations and 
14 (35%) were KIT wild-type. There were 13 deletions, 6 substi-
tutions (point mutations), 3 deletion-substitutions (deletion 
plus substitution), 3 duplications and 1 insertion. Twenty-five 
mutations occurred in exon 11 and 1 in exon 9. KIT mutations 
were grouped into two risk groups. The low-risk (lr) group 
included 12 cases with substitutions (6), deletion-substitutions 
(3) and duplications (3). The high-risk (Hr) group included 
14 cases with deletions (13) and an insertion (1). 
PDGFRA mutations were found in 6 out of 40 cases (15%); 
34 (85%) were wild-type for PDGFRA. There were 4 deletions 
and 2 substitutions (point mutations). Five mutations occurred 
in exon 18 and 1 in exon 12. due to the small number of mutated 
cases, PDGFRA mutations were considered as a single group. 
eight patients (20%) were KIT and PDGFRA wild-type.
PdGFra immunopositivity was found in 23 cases 
(57.5%), 5 of which (12.5%) showed strong immunoreactivity 
with prominent perinuclear ‘dotlike’ accentuation (Fig. 1c). 
Association between type of KIT/PDGFRA mutation and 
clinicopathological variables. GiSTs with PdGFra muta-
tions had a smaller size and a lower mitotic index (Mi) and 
Ki67 score than tumors with KIT Hr (p=0.01). 
at diagnosis, 83.3% of patients with PDGFRA mutations 
were asymptomatic, in contrast to only 25% of KIT/PDGFRA 
wild-type, 21.4% of KIT Hr and 16.7% of KIT lr patients 
(p=0.02). adjacent organ invasion at diagnosis was found in 
35.7% of KIT Hr and in 12.5% of KIT/PDGFRA wild-type 
cases, but not in PDGFRA mutated or KIT lr cases (p=0.04). 
distant metastasis occurred in 50% of KIT Hr and in 37.5% of 
KIT/PDGFRA wild-type cases, but in only 16.7% of PDGFRA 
mutated patients; no metastasis was observed in patients with 
KIT lr (p=0.03). additionally, relapse occurred in 50% of 
KIT/PDGFRA wild-type and in 35.7% of KIT Hr cases, but 
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in only 16.7% of PDGFRA mutated cases; no relapse occurred 
in patients with KIT lr (p=0.05).
PdGFra immunopositivity was found in all PDGFRA 
mutated cases, and in 62.5% of KIT/PDGFRA wild-type, 
58.3% of KIT lr and only 35.7% of KIT Hr cases. The 
difference between these results is of borderline significance 
(p=0.06). notably, PdGFra ‘dotlike’ immunopositivity 
(Fig. 1c) was found in 5 out of 6 (83.3%) cases with PDGFRA 
mutations, but not in KIT Hr, KIT lr or KIT/PDGFRA wild-
type cases (p<0.0001). all ‘dotlike’ immunopositive cases 
were wild-type for KIT, 4 carried a PDGFRA deletion and 1 a 
PDGFRA substitution (point mutation).
The results are shown in Table i.
Correlation of type of KIT/PDGFRA mutation and PDGFRA 
immunostaining with disease-free survival. out of 40 patients, 
30 (75%) were free of disease and 10 (25%) relapsed. The 
3- and 5-year dFS rates for the whole series were 81 and 
58%, respectively. at the 3-year follow-up, all the patients 
with PDGFRA mutations or KIT lr were free of disease, in 
contrast to only 87% of those with KIT/PDGFRA wild-type 
and 53% of those with KIT Hr. The difference was only of 
borderline significance (p=0.1); however, the DFS of KIT lr 
patients was significantly longer than that of KIT Hr (p=0.05) 
or KIT/PDGFRA wild-type patients (p=0.01) (Table ii).
The 3- and 5-year dFS rates for patients with positive 
PdGFra immunostaining were 95 and 72%, respectively, 
but only 63 and 42%, respectively, for those with negative 
PdGFra immunostaining (p=0.04) (Table ii and Fig. 2).
Discussion
The results of the present study show that GiSTs bearing KIT 
Hr mutations were larger and had a higher Mi than GiSTs 
with KIT lr mutations. also, 64.3% of KIT Hr patients were 
at high risk of aggressive tumor behavior, as compared to 
33.3% of those with KIT lr (p=0.04); 35.7% presented with 
invasion into adjacent organs and relapsed, while no patients 
with KIT lr showed organ invasion or relapsed (p=0.03); 
distant metastases were found in 50% of KIT Hr, but in 
no KIT lr cases (p=0.003). Furthermore, only 53% of KIT 
Hr patients were free of disease at the 5-year follow-up, in 
contrast to 100% of the KIT lr cases (p=0.05).
Our findings are in accordance with several studies 
reporting a poor prognosis for GiSTs with KIT deletions (5-13) 
or insertions (5,11,13), particularly those affecting the 557/558 
codon. indeed, our 2 cases with deletions in codons 557-558 
showed metastatic disease at diagnosis and died at 6 and 
11 months after surgery, respectively. However, our results are 
contradictory to a few studies reporting that KIT mutations 
are a ubiquitous feature of GiSTs, either malignant or benign 
(15,16), and that the type of KIT mutation has no prognostic 
value (17). Moreover, KIT duplications have been described 
in a few malignant advanced GiSTs in series from imatinib 
trials (18,19).
PDGFRA mutations were associated with rather indolent 
tumors; indeed, PDGFRA mutated GiSTs had a smaller size 
and lower Mi and Ki67 scores than GiSTs with KIT Hr muta-
tions. only 1 patient presented with symptoms (contrary to 
80% of patients with KIT mutations; p=0.02); none were at 
high risk of aggressive tumor behavior or experienced inva-
sion into the adjacent organs; only 1 developed metastasis 
or relapsed; lastly, all were free of disease at the 40-month 
follow-up. our results are in line with a few reports showing 
a favorable outcome for GiSTs with PDGFRA mutations 
(4,20). However, all cases with PDGFRA mutations were 
gastric GiSTs, and it is known that gastric GiSTs have a rather 
good prognosis. in our series, too, the median survival for the 
27 gastric GiSTs was 70.8 vs. 13.5 months for the 9 GiSTs 
located in the small bowel and 4.8 months for those located in 
the large bowel (p=0.0004).
notably, PdGFra immunostaining tended to be asso-
ciated with KIT or PDGFRA mutational status; indeed, 
positive PdGFra immunostaining was present in all 
Figure 1. (a) Weak PdGFra immunopositivity in spindle cell GiST. Most 
cells show faint diffuse cytoplasmic staining. (B) Moderately positive 
PdGFra immunostaining in epithelioid GiST. a few cells show a perinu-
clear ‘dotlike’ accentuation (so-called Golgi pattern). (c) Strong PdGFra 
immunopositivity with prominent ‘dotlike’ Golgi pattern in epithelioid 
GIST. Original magnification, x400.
  A
  B
  C
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PDGFRA mutated cases, but in only 35.7% of KIT Hr, 58.3% 
of KIT lr and 62.5% of KIT/PDGFRA wild-type cases. in 
particular, a strong perinuclear ‘dotlike’ staining (Golgi 
pattern) was found in 83.3% of PDGFRA mutated cases, but 
not in those with KIT mutations or in KIT/PDGFRA wild-
type cases. Our findings confirm previous reports (24-26) 
and indicate that this peculiar PdGFra-positive staining is a 
rather specific marker of PDGFRA mutations, and is typically 
absent in all KIT mutated cases. Further study is required to 
clarify the biological meaning of the ‘dotlike’ decoration.
Table i. association between type of KIT/PDGFRA mutation and clinicopathological variables.
 PDGFRA KIT Hr  KIT lr   KIT/
 deletions/ deletions/ substitutions/ PDGFRA
 substitutions insertion deletion-substitutions/ wild-type
 (n=6) (n=14) duplications (n=12) (n=8)
Variable no. (%) no. (%) no. (%) no. (%)
Symptoms at diagnosis
  Present 1 (16.7) 11 (78.6) 10 (83.3) 6 (75.0) χ2=9.73
  absent 5 (83.3)   3 (21.4)   2 (16.7) 2 (25.0) p=0.02
Site
  Stomach 6  (100)   7 (50.0)   9 (75.0) 7 (87.5) χ2=6.77
  other 0      (0)   7 (50.0)   3 (25.0) 1 (12.5) p=0.07
Histologic type
  Spindle cell 1 (16.7) 10 (71.4)   8 (66.7) 6 (75.0) χ2=6.47
  non-spindle cell 5 (83.3)   4 (28.6)   4 (33.3) 2 (25.0) p=0.09
risk of aggressive behavior
  Very low 1 (16.7)   2 (14.3)   0      (0) 1 (12.5) χ2=13.45
  low 3 (50.0)   0      (0)   4 (33.3) 1 (12.5) p=0.14
  intermediate 2 (33.3)   3 (21.4)   4 (33.3) 2 (25.0)
  High 0      (0)   9 (64.3)   4 (33.3) 4 (50.0)
adjacent organ invasion
at diagnosis
  Present 0      (0)   5 (35.7)   0      (0) 1 (12.5) χ2=7.92
  absent 6  (100)   9 (64.3) 12  (100) 7 (87.5) p=0.04
distant metastasis
  Present 1 (16.7)   7 (50.0)   0      (0) 3 (37.5) χ2=8.86
  absent 5 (83.3)   7 (50.0) 12  (100) 5 (62.5) p=0.03
relapse
  Present 1 (16.7)   5 (35.7)   0      (0) 4 (50.0) χ2=7.74
  absent 5 (83.3)   9 (64.3) 12  (100) 4 (50.0) p=0.05
PdGFra immunostaining
  negative 0      (0)   9 (64.3)   5 (41.7) 3 (37.5) χ2=7.23
  Positive 6  (100)   5 (35.7)   7 (58.3) 5 (62.5) p=0.06
PdGFra ‘dotlike’
immunopositivity
  Present 5 (83.3)   0      (0)   0      (0) 0      (0) χ2=32.38
  absent 1 (16.7) 14  (100) 12  (100) 8  (100) p<0.0001
Variable Mean ± Sd Mean ± Sd Mean ± Sd Mean ± Sd
Size (cm) 3.16±1.32a 8.57±6.84b  6.41±3.05c   4.62±2.26 p=0.08
Mitotic index   3.5±2.58d 30.35±35.96e  6.58±7.56f 22.75±37.1 p=0.09
Ki67 score   3.0±1.67g 9.5±7.9h 5.25±6.73 10.87±15.4 p=0.28
Hr, high-risk group; lr, low-risk group. a vs. b, p=0.01; a vs. c, p=0.006; d vs. e, p=0.01; e vs. f, p=0.02; g vs. h, p=0.01.
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The importance of PdGFra immunostaining in 
GiSTs is further supported by its prognostic value: 7 of 17 
immunonegative cases (41.2%) relapsed, while only 3 of 23 
(13%) immunopositive cases did (p=0.04). Moreover, at the 
5-year follow-up, 72% of PdGFra immunopositive patients 
were free of disease, while only 42% of immunonegative 
patients were.
in conclusion, with the limitation due to the relatively 
small number of cases, our results confirm that the type of 
KIT mutation is associated with various biological and 
clinical behaviors of GiSTs, and that PDGFRA mutations are 
associated with rather benign tumors. They also indicate that 
a strong PDGFRA immunopositivity reflects PDGFRA muta-
tional status in GiSTs and is associated with a good prognosis. 
Therefore, PdGFra immunostaining should be a useful 
additional marker in the diagnostic and prognostic evaluation 
of GiSTs.
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